{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:17:58Z","timestamp":1785208678230,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-025-07441-8","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T12:57:23Z","timestamp":1760360243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The impact of fluoxetine on obesity and diabetes-related biomarkers in overweight and obese individuals: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Guixia","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hainan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periyannan","family":"Velu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Safargar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousalya","family":"Prabahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"4","key":"7441_CR1","doi-asserted-by":"publisher","DOI":"10.52965\/001c.39580","volume":"10","author":"AN Edinoff","year":"2022","unstructured":"Edinoff AN, et al. Selective serotonin reuptake inhibitors and associated bleeding risks: a narrative and clinical review. Health Psychol Res. 2022;10(4):39580.","journal-title":"Health Psychol Res"},{"key":"7441_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2832-3-2","volume":"3","author":"A Rossi","year":"2004","unstructured":"Rossi A, Barraco A, Donda P. Fluoxetine: a review on evidence based medicine. Ann Gen Hosp Psychiatry. 2004;3:1\u20138.","journal-title":"Ann Gen Hosp Psychiatry"},{"issue":"1","key":"7441_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/biomedicines10010056","volume":"10","author":"A Dimoula","year":"2021","unstructured":"Dimoula A, et al. Off-target effects of antidepressants on vascular function and structure. Biomedicines. 2021;10(1):56.","journal-title":"Biomedicines"},{"key":"7441_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112040","author":"D Liu","year":"2025","unstructured":"Liu D, et al. The effect of Fluoxetine on lipid profiles in overweight or obese individuals: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2025. https:\/\/doi.org\/10.1016\/j.diabres.2025.112040.","journal-title":"Diabetes Res Clin Pract"},{"key":"7441_CR5","doi-asserted-by":"crossref","unstructured":"Serralde-Zuniga AE et al. Fluoxetine for adults who are overweight or obese. Cochrane Database Syst Reviews, 2019 ;10(10):CD011688.","DOI":"10.1002\/14651858.CD011688.pub2"},{"issue":"11","key":"7441_CR6","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/oby.22969","volume":"28","author":"H Gill","year":"2020","unstructured":"Gill H, et al. Antidepressant medications and weight change: a narrative review. Obesity. 2020;28(11):2064\u201372.","journal-title":"Obesity"},{"key":"7441_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ocarto.2024.100472","author":"Q Qi","year":"2024","unstructured":"Qi Q, et al. Obesity medications: a narrative review of current and emerging agents. Osteoarthritis Cartilage Open. 2024. https:\/\/doi.org\/10.1016\/j.ocarto.2024.100472.","journal-title":"Osteoarthritis Cartilage Open"},{"issue":"7","key":"7441_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13210","volume":"22","author":"KA van Galen","year":"2021","unstructured":"van Galen KA, Ter Horst KW, Serlie MJ. Serotonin, food intake, and obesity. Obes Rev. 2021;22(7):e13210.","journal-title":"Obes Rev"},{"issue":"1","key":"7441_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01738-y","volume":"9","author":"L Cui","year":"2024","unstructured":"Cui L, et al. Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduct Target Ther. 2024;9(1):30.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"7441_CR10","doi-asserted-by":"publisher","first-page":"e759","DOI":"10.1038\/tp.2016.25","volume":"6","author":"S Lee","year":"2016","unstructured":"Lee S, et al. Is increased antidepressant exposure a contributory factor to the obesity pandemic? Translational Psychiatry. 2016;6(3):e759\u2013759.","journal-title":"Translational Psychiatry"},{"issue":"1","key":"7441_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","volume":"34","author":"S Klein","year":"2022","unstructured":"Klein S, et al. Why does obesity cause diabetes? Cell Metab. 2022;34(1):11\u201320.","journal-title":"Cell Metab"},{"issue":"3","key":"7441_CR12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3349\/ymj.2016.57.3.674","volume":"57","author":"SH Jung","year":"2016","unstructured":"Jung SH, Ha KH, Kim DJ. Visceral fat mass has stronger associations with diabetes and prediabetes than other anthropometric obesity indicators among Korean adults. Yonsei Med J. 2016;57(3):674.","journal-title":"Yonsei Med J"},{"key":"7441_CR13","doi-asserted-by":"crossref","unstructured":"Shang C et al. Association Between Visceral Obesity and Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Retrospective Study. Diabetes, Metabolic Syndrome and Obesity, 2024: pp. 2869\u20132880.","DOI":"10.2147\/DMSO.S470836"},{"issue":"4","key":"7441_CR14","first-page":"3073","volume":"22","author":"H Yang","year":"2020","unstructured":"Yang H, et al. Fluoxetine regulates glucose and lipid metabolism via the PI3K\u2013AKT signaling pathway in diabetic rats. Mol Med Rep. 2020;22(4):3073\u201380.","journal-title":"Mol Med Rep"},{"issue":"9","key":"7441_CR15","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","volume":"89","author":"D Moher","year":"2009","unstructured":"Moher D, et al. Reprint\u2014preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther. 2009;89(9):873\u201380.","journal-title":"Phys Ther"},{"key":"7441_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"7650","key":"7441_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"key":"7441_CR18","unstructured":"Borenstein M, et al. Introduction to meta-analysis. Wiley; 2011."},{"issue":"1","key":"7441_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.","journal-title":"BMC Med Res Methodol"},{"issue":"7109","key":"7441_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"key":"7441_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clineuro.2018.02.029","volume":"168","author":"Y He","year":"2018","unstructured":"He Y, et al. Effect of fluoxetine on three-year recurrence in acute ischemic stroke: a randomized controlled clinical study. Clin Neurol Neurosurg. 2018;168:1\u20136.","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"7441_CR22","first-page":"90","volume":"35","author":"AM Al-Helli","year":"2015","unstructured":"Al-Helli AM, et al. Effects of fluoxetine, Omega 3, or their combination on serum leptin in Iraqi obese subjects. Int J Pharm Sci Rev Res. 2015;35(1):90\u20135.","journal-title":"Int J Pharm Sci Rev Res"},{"issue":"8","key":"7441_CR23","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/ijo.2013.225","volume":"38","author":"H Suplicy","year":"2014","unstructured":"Suplicy H, et al. A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. Int J Obes. 2014;38(8):1097\u2013103.","journal-title":"Int J Obes"},{"issue":"9","key":"7441_CR24","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.2337\/db08-0236","volume":"57","author":"VJ Briscoe","year":"2008","unstructured":"Briscoe VJ, et al. Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy individuals. Diabetes. 2008;57(9):2453\u201360.","journal-title":"Diabetes"},{"issue":"6","key":"7441_CR25","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1590\/S0004-27302006000600007","volume":"50","author":"C Guimar\u00e3es","year":"2006","unstructured":"Guimar\u00e3es C, et al. Tolerability and effectiveness of fluoxetine, Metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arq Bras Endocrinol Metabol. 2006;50(6):1020\u20135.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"6","key":"7441_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/01.jcp.0000095341.32154.8f","volume":"23","author":"MYH Moosa","year":"2003","unstructured":"Moosa MYH, et al. African women with depression: the effect of Imipramine and Fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol. 2003;23(6):549\u201352.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"7441_CR27","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/sj.npp.1300089","volume":"28","author":"JR Bustillo","year":"2003","unstructured":"Bustillo JR, et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology. 2003;28(3):527\u20139.","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"7441_CR28","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1176\/ajp.156.8.1170","volume":"156","author":"D Michelson","year":"1999","unstructured":"Michelson D, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156(8):1170\u20136.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"7441_CR29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1037\/0022-006X.67.1.124","volume":"67","author":"B Borrelli","year":"1999","unstructured":"Borrelli B, et al. Weight suppression and weight rebound in ex-smokers treated with fluoxetine. J Consult Clin Psychol. 1999;67(1):124\u201331.","journal-title":"J Consult Clin Psychol"},{"issue":"2","key":"7441_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/sj.ijo.0800372","volume":"21","author":"P Maheux","year":"1997","unstructured":"Maheux P, et al. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord. 1997;21(2):97\u2013102.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"4","key":"7441_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/j.1550-8528.1996.tb00247.x","volume":"4","author":"JC Daubresse","year":"1996","unstructured":"Daubresse JC, et al. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res. 1996;4(4):391\u20136.","journal-title":"Obes Res"},{"issue":"5","key":"7441_CR32","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1464-5491.1995.tb00505.x","volume":"12","author":"VM Connolly","year":"1995","unstructured":"Connolly VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet Med. 1995;12(5):416\u20138.","journal-title":"Diabet Med"},{"issue":"12","key":"7441_CR33","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/0026-0495(95)90077-2","volume":"44","author":"L Breum","year":"1995","unstructured":"Breum L, et al. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism. 1995;44(12):1570\u20136.","journal-title":"Metabolism"},{"issue":"2","key":"7441_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/j.1550-8528.1994.tb00641.x","volume":"2","author":"M Visser","year":"1994","unstructured":"Visser M, et al. No specific effect of Fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obes Res. 1994;2(2):152\u20139.","journal-title":"Obes Res"},{"issue":"1","key":"7441_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1464-5491.1994.tb00238.x","volume":"11","author":"M O\u2019Kane","year":"1994","unstructured":"O\u2019Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med. 1994;11(1):105\u201310.","journal-title":"Diabet Med"},{"issue":"3","key":"7441_CR36","first-page":"129","volume":"18","author":"DJ Goldstein","year":"1994","unstructured":"Goldstein DJ, et al. Fluoxetine: A randomized clinical trial in the treatment of obesity. Int J Obes. 1994;18(3):129\u201335.","journal-title":"Int J Obes"},{"issue":"3","key":"7441_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/npp.1993.56","volume":"9","author":"J Wurtman","year":"1993","unstructured":"Wurtman J, et al. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. Neuropsychopharmacology. 1993;9(3):201\u201310.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"7441_CR38","first-page":"247","volume":"17","author":"M Visser","year":"1993","unstructured":"Visser M, et al. The effect of Fluoxetine on body weight, body composition and visceral fat accumulation. Int J Obes Relat Metab Disord. 1993;17(5):247\u201353.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"2","key":"7441_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/j.1550-8528.1993.tb00597.x","volume":"1","author":"DJ Goldstein","year":"1993","unstructured":"Goldstein DJ, et al. Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obes Res. 1993;1(2):92\u20138.","journal-title":"Obes Res"},{"issue":"Suppl 4","key":"7441_CR40","first-page":"S67","volume":"16","author":"DS Gray","year":"1992","unstructured":"Gray DS, et al. A randomized double-blind clinical trial of Fluoxetine in obese diabetics. Int J Obes Relat Metab Disord. 1992;16(Suppl 4):S67\u201372.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"5","key":"7441_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/0306-4530(91)90008-H","volume":"16","author":"OF Pomerleau","year":"1991","unstructured":"Pomerleau OF, et al. Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake. Psychoneuroendocrinology. 1991;16(5):433\u201340.","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"7441_CR42","first-page":"237","volume":"15","author":"H Pijl","year":"1991","unstructured":"Pijl H, et al. Effect of serotonin re-uptake Inhibition by Fluoxetine on body weight and spontaneous food choice in obesity. Int J Obes. 1991;15(3):237\u201342.","journal-title":"Int J Obes"},{"issue":"2","key":"7441_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/ajcn\/54.2.321","volume":"54","author":"LL Darga","year":"1991","unstructured":"Darga LL, et al. Fluoxetine\u2019s effect on weight loss in obese subjects. Am J Clin Nutr. 1991;54(2):321\u20135.","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"7441_CR44","first-page":"635","volume":"13","author":"LR Levine","year":"1989","unstructured":"Levine LR, et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: A dose-response study (with a commentary by Michael Weintraub). Int J Obes. 1989;13(5):635\u201345.","journal-title":"Int J Obes"},{"issue":"Suppl 3","key":"7441_CR45","first-page":"185","volume":"11","author":"LR Levine","year":"1987","unstructured":"Levine LR, Rosenblatt S, Bosomworth J. Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. Int J Obes. 1987;11(Suppl 3):185\u201390.","journal-title":"Int J Obes"},{"key":"7441_CR46","doi-asserted-by":"publisher","first-page":"1161521","DOI":"10.3389\/fendo.2023.1161521","volume":"14","author":"R Ruze","year":"2023","unstructured":"Ruze R, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:1161521.","journal-title":"Front Endocrinol"},{"key":"7441_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2023.106030","volume":"150","author":"I Baenas","year":"2023","unstructured":"Baenas I, et al. Neuroendocrinological factors in binge eating disorder: a narrative review. Psychoneuroendocrinology. 2023;150:106030.","journal-title":"Psychoneuroendocrinology"},{"issue":"10","key":"7441_CR48","doi-asserted-by":"publisher","first-page":"979","DOI":"10.4088\/JCP.09r05346blu","volume":"71","author":"A Serretti","year":"2010","unstructured":"Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71(10):979.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"7441_CR49","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1210\/jc.2014-3421","volume":"100","author":"JP Domecq","year":"2015","unstructured":"Domecq JP, et al. Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(2):363\u201370.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"7441_CR50","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/WNF.0b013e318064579f","volume":"30","author":"PN Dannon","year":"2007","unstructured":"Dannon PN, et al. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol. 2007;30(6):326\u201334.","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"7441_CR51","doi-asserted-by":"publisher","first-page":"e21551","DOI":"10.1371\/journal.pone.0021551","volume":"6","author":"Z Ye","year":"2011","unstructured":"Ye Z, et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. PLoS ONE. 2011;6(7):e21551.","journal-title":"PLoS ONE"},{"key":"7441_CR52","doi-asserted-by":"crossref","unstructured":"Chao AM et al. Clinical insight on semaglutide for chronic weight management in adults: patient selection and special considerations. Drug design, development and therapy, 2022: pp. 4449\u20134461.","DOI":"10.2147\/DDDT.S365416"},{"issue":"2","key":"7441_CR53","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s40200-021-00899-9","volume":"20","author":"A Okamoto","year":"2021","unstructured":"Okamoto A, et al. Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists. J Diabetes Metab Disord. 2021;20(2):2121\u20138.","journal-title":"J Diabetes Metab Disord"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07441-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-07441-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07441-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:24:41Z","timestamp":1760369081000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-07441-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7441"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-07441-8","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"977"}}